Modifying Graft-versus-Host Disease in a Humanized Mouse Model by Targeting Macrophages or B-Cells

Figure 1

Survival of RAG2^-/-γc^-/- mice after introducing HuPBMCs with or without clodronate-driven depletion of macrophages. (a) Results from experiment 1. Mean survival with macrophage depletion (dotted line) was 13 days (SD 0), mean survival without macrophage depletion (continuous line) 36.67 days (SD 7.174) after intravenous injection with huPBMCs. (b) Results from experiment 2. Mean survival 32.88 days (SD 19.0) with macrophage depletion (dotted line) and mean survival 64.63 days (SD 26.9) without macrophage depletion (continuous line, pooled data from both donors after huPBMC injection).

(a)

(b)